Image

    Role of Sodium-Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review

    January 2025 in “ touchREVIEWS in Endocrinology ”
    A B Kamrul-Hasan, Sunetra Mondal, Fatema Tuz Zahura Aalpona … Deep Dutta
    Studysummary This study suggests that sodium-glucose cotransporter-2 inhibitors, alone or with metformin or GLP1RA, may improve metabolic and hormonal parameters in women with polycystic ovary syndrome.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on touchendocrinology.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Recommendations From The 2023 International Evidence-Based Guideline For The Assessment And Management Of Polycystic Ovary Syndrome The Journal of Clinical Endocrinology and Metabolism · 2023
    2. Polycystic Ovary Syndrome: Insight Into Pathogenesis and a Common Association With Insulin Resistance Clinical Medicine · 2016
    3. Polycystic Ovary Syndrome: Insight Into Pathogenesis and a Common Association With Insulin Resistance Clinical Medicine · 2015